TABLE 1

SLNs Identified in the Study Patients

SLNsLymphatic drainage
PatientDose* (MBq)Scan 1Scan 2Second-echelon nodesClassicAberrantNonlymphatic
SPECT 182.6L external iliac, L common iliacL external iliac, L common iliacRetroperitoneal (paraaortic)YesNoNo
SPECT 231.0R internal iliacR internal iliac, L internal iliac (probable)YesNoNo
SPECT 319.9R external iliacR external iliacR common iliacYesNoNo
PET 116.1R internal iliac, L perivesical, L internal iliac, L external iliac (probable)R internal iliac, L perivesicalYesYesNo
PET 28.7L internal iliac, L anterior periprostatic into L inferior pubic ramusL internal iliac, L anterior periprostatic into L inferior pubic ramusL internal iliac 2YesNoYes
PET 321.0L periprostaticL periprostatic, R periprostaticYesNoNo
PET 411.2R mesorectal, L external iliacR mesorectal, L external iliacR presacralYesYesNo
PET 53.1L internal iliac, L inguinalL internal iliac (disappears), L inguinalL common iliac, distal thoracic duct (Virchow node)YesYesNo
  • * Injected dose of 99mTc-radiocolloid for SPECT and 68Ga-nanocolloid for PET.

  • SLNs were found both in classic sites of regional spread and in aberrant sites (boldface font). First 3 patients underwent 99mTc-radiocolloid SPECT/CT, and next 5 underwent 68Ga-nanocolloid PET/CT. Scans were obtained about 45 and 100 min after tracer injection.